Nidanilimab

What is Nidanilimab?

Nidanilimab is a fully humanized, low-fucose IgG1 monoclonal antibody that binds IL1RAP, a co-receptor of the IL-1 and IL-33 receptors that is upregulated on certain tumor cells. By blocking IL1RAP signaling it reduces NF-kB activation and tumor-promoting cytokine secretion, and it also engages natural killer cells through antibody-dependent cellular cytotoxicity. It is being studied in metastatic microsatellite stable colorectal carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Nadunolimab

Drug type

Monoclonal antibody

Targets

Interleukin-1 receptor accessory protein (IL1RAP)

Mechanism

Antagonist of Interleukin-1 receptor accessory protein (IL1RAP)

Pathways

IL-1 and IL-33 signaling, NF-kB activation, antibody-dependent cellular cytotoxicity

Therapy area

Oncology

Developer

Cantargia AB

In trials of

CHRS

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1/2

UNII

ND296JF21I

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Microsatellite Stable Colorectal Carcinoma

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT07281716

Updated Oct 11, 2026.